Powered by a deal with Pfizer Inc., Glycomimetics Inc. is looking to solidify further its position in the race for therapies that would treat vaso-occlusive crises (VOCs) in sickle cell disease (SCD). The Gaithersburg, Md.-based company, which filed for a proposed initial public offering (IPO), but did not specify the targeted number of shares or price range, is developing GMI-1070 (rivipansel sodium) with Pfizer, of New York. Read More
SAN FRANCISCO – Over the next two days, the BIO Investor Forum will be under way, drawing more than 600 attendees from more than 200 companies, and more than 220 investors. And the trends are positive. Read More
The initial public offering (IPO) palooza continued into October with two more filings, including one by Karyopharm Therapeutics Inc. seeking to raise up to $80 million. Karyopharm’s S-1 was filed just two months after the biotech closed a $19 million Series B extension that propelled its venture financing to $97.2 million. Read More
Despite rare Saturday sessions, the House and Senate appear to be spinning their wheels when it comes to ending a partial government shutdown that’s headed into its second week due to Congress’ inability to agree on fiscal 2014 funding measures.Read More
LONDON – Xention Ltd. has taken a major step forward, out-licensing its atrial fibrillation treatment XEN-DO103 in a $163 million-plus joint development agreement in which the UK biotech will retain full rights to the product in the U.S. and Japan. Read More
The 2013 Nobel Prize in Physiology or Medicine was awarded to James Rothman, Randy Schekman and Thomas Sudhof “for their discoveries of machinery regulating vesicle traffic, a major transport system in our cells.” Read More
• Debiopharm Group, of Lausanne, Switzerland, signed an exclusive research collaboration with the Experimental Therapeutics Centre at Singapore’s Agency for Science, Technology and Research to develop oral small molecules targeting tumors with genetic lesions. Read More
• Cardiome Pharma Corp., of Vancouver, British Columbia, said data from an observational, retrospective study including 251 recent-onset atrial fibrillation (AF) patients receiving Brinavess (vernakalant) treatments during the period between Jan. 15, 2011, and April 15, 2013, showed that 70 percent converted with a median time of 11 minutes. Read More
